Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
25 Sep 2020 7:00 am
RNS
Directorate Change
21 Sep 2020 7:05 am
RNS
Lynparza EU recommendation in prostate cancer
  7:00 am
RNS
Lynparza EU recommendation in ovarian cancer
  7:00 am
RNS
Tagrisso reduced early lung cancer brain recurrenc
10 Sep 2020 7:01 am
RNS
AstraZeneca to list all US securities on Nasdaq
  7:00 am
RNS
Fasenra PhIII OSTRO trial met co-primary endpoints
01 Sep 2020 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Imfinzi approved in EU for small cell lung cancer
  7:00 am
RNS
Farxiga reduces CKD progression and risk of death
25 Aug 2020 7:00 am
RNS
Ph I trial begins for COVID-19 monoclonal antibody
21 Aug 2020 7:00 am
RNS
Imfinzi approved in Japan for SCLC
18 Aug 2020 7:00 am
RNS
Imfinzi US Priority Review; four-week, fixed dose
04 Aug 2020 7:00 am
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2020 3:00 pm
RNS
Total Voting Rights
30 Jul 2020 7:25 am
RNS
Tagrisso US BTD for EGFRm adjuvant lung cancer
  7:18 am
RNS
AZN: H1 2020 results
29 Jul 2020 7:00 am
RNS
Board Committee Changes
28 Jul 2020 7:00 am
RNS
Farxiga DAPA-CKD trial met all endpoints
27 Jul 2020 7:10 am
RNS
Calquence receives positive CHMP opinion for CLL
  7:05 am
RNS
Imfinzi recommended for EU approval in SCLC
  7:00 am
RNS
AstraZeneca enters collaboration in oncology
24 Jul 2020 7:00 am
RNS
Breztri Aerosphere approved in the US for COPD
22 Jul 2020 3:00 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
21 Jul 2020 3:00 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
20 Jul 2020 2:41 pm
RNS
COVID-19 vaccine Phase I/II showed immune response
16 Jul 2020 7:00 am
RNS
Director Declaration
09 Jul 2020 7:00 am
RNS
Brilinta granted US FDA Priority Review for stroke
08 Jul 2020 7:00 am
RNS
Lynparza approved in the EU for pancreatic cancer
01 Jul 2020 3:00 pm
RNS
Total Voting Rights
30 Jun 2020 3:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Selumetinib granted Japan orphan drug designation
17 Jun 2020 3:03 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
15 Jun 2020 7:00 am
RNS
Agreement to Supply Europe with COVID-19 Vaccine
11 Jun 2020 7:00 am
RNS
EMTN Programme Routine Technical Update
01 Jun 2020 3:00 pm
RNS
Total Voting Rights
  3:00 pm
RNS
Block listing Interim Review
  7:00 am
RNS
Lynparza EU CHMP opinion in pancreatic cancer
  7:00 am
RNS
Brilinta obtains additional US approval
29 May 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  1:00 pm
RNS
Enhertu DESTINY-Gastric01 results from ASCO 2020
  1:00 pm
RNS
Imfinzi sustained overall survival in CASPIAN
  7:00 am
RNS
Tagrisso unprecedented adjuvant lung cancer data
26 May 2020 10:30 am
RNS
Director/PDMR Shareholding
22 May 2020 7:00 am
RNS
Enhertu US orphan designation in gastric cancer
21 May 2020 7:00 am
RNS
AstraZeneca advances response to COVID-19 outbreak
20 May 2020 7:00 am
RNS
Lynparza approved in the US for prostate cancer
18 May 2020 7:00 am
RNS
Enhertu US Breakthrough status for lung cancer
  7:00 am
RNS
Bevespi Aerosphere approved in China for COPD
11 May 2020 7:00 am
RNS
Enhertu designated gastric cancer BTD
  7:00 am
RNS
Brazikumab rights recovered by AstraZeneca
  7:00 am
RNS
Lynparza gets broader US ovarian cancer approval
06 May 2020 7:00 am
RNS
Farxiga approved by FDA for heart failure (HFrEF)
01 May 2020 3:00 pm
RNS
Total Voting Rights
29 Apr 2020 4:00 pm
RNS
Result of AGM
  7:00 am
RNS
AZN: first-quarter 2020 results
24 Apr 2020 7:00 am
RNS
Lynparza shows overall survival in prostate cancer
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t